Suzanne L Topalian
Affiliation: Johns Hopkins University
- Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011Ivan Martinez Forero
Centro de Investigación Médica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain
J Transl Med 10:108. 2012..The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace...
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
Curr Opin Immunol 24:207-12. 2012..Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy...
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
N Engl J Med 366:2443-54. 2012..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1...
- Cancer immunotherapy comes of ageSuzanne L Topalian
Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 29:4828-36. 2011..Unlike conventional cancer therapies, most immunotherapies are active and dynamic, capable of inducing immune memory to propagate a successful rebalancing of the equilibrium between tumor and host...
- Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyEvan J Lipson
Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
Clin Cancer Res 19:462-8. 2013..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective...
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer
Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 28:3167-75. 2010..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer
Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
N Engl J Med 366:2455-65. 2012..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models...
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaSofia Lyford-Pike
Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Cancer Res 73:1733-41. 2013....
- Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeJanis M Taube
Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Sci Transl Med 4:127ra37. 2012..These observations suggest that therapies that block this pathway may benefit patients with B7-H1(+) tumors...
- Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapyFlorence R Depontieu
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Proc Natl Acad Sci U S A 106:12073-8. 2009..This previously undescribed demonstration of MHC II-restricted phosphopeptides recognizable by human CD4(+) T cells provides potential new targets for cancer immunotherapy...